ArticleJNCI cancer spectrum2026
Racial disparities and utilization trends of first-line targeted therapies for metastatic breast cancer.
Article in JNCI cancer spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-world treatment patterns among patients diagnosed with hormone receptor-positive metastatic breast cancer in the USA.British journal of clinical pharmacology · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundWe aimed to determine temporal trends and racial disparities in utilization and time to treatment initiation of cyclin dependent kinase 4/6 (CDK4/6) inhibitors and pertuzumab for first-line metastatic breast cancer.
methodsWe extracted data from a nationwide electronic health record-derived deidentified database. Female patients aged 18 years and older with estrogen receptor-positive and HER2-negative or HER2-positive metastatic breast cancer eligible for CDK4/6 inhibitors (March 2015-October 2021) or pertuzumab (July 2012-September 2021) were included. Our outcomes were adjusted temporal trends in the proportion of patients receiving respective therapies using logistic regression with natural cubic splines for time trends and tested for changes in utilization over time within and between racial groups (non-Hispanic White or non-Hispanic Black). Similar models using linear regression estimated mean time to treatment initiation.
resultsA total of 5173 (non-Hispanic White = 4478; non-Hispanic Black = 695) estrogen receptor-positive and HER2-negative and 2321 (non-Hispanic White = 1915; non-Hispanic Black = 406) HER2-positive metastatic breast cancer patients were included. There were statistically significant differences in the proportion initiating CDK4/6 inhibitors over time within racial groups (non-Hispanic White: 23.5%, 95% confidence interval [CI] = 20.1% to 27.3%, in 2015 to 53.8%, 95% CI = 48.6% to 59.0%, in 2021; non-Hispanic Black: 20.6%, 95% CI = 11.9% to 33.0%, in 2015 to 73.6%, 95% CI = 61.7% to 83.0%, in 2021) and between groups (P = .009). There was a statistically significant increase in utilization of pertuzumab within both racial groups over time (P < .001), but no statistically significant difference between groups (P = .45). Time to treatment initiation decreased over time with no statistically significant differences in time to treatment initiation trends between the 2 groups.
conclusionsUtilization of targeted therapies increased over time, however non-Hispanic Black patients were less likely to receive CDK4/6 inhibitors compared with non-Hispanic White. Approximately half of eligible patients did not receive pertuzumab. Further research is needed to understand mediators and design interventions to address underutilization of these therapies and those contributing to racial disparities in CDK4/6 inhibitor utilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.